Madrigal Pharmaceuticals, Inc.
MDGL
$532.58
-$14.08-2.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 38.62% | -61.15% | 48.70% | -170.07% | 42.27% |
| Total Depreciation and Amortization | 29.22% | -59.07% | 1.62% | 341.90% | -0.69% |
| Total Amortization of Deferred Charges | 3.34% | -4.06% | 42.25% | -11.32% | -14.91% |
| Total Other Non-Cash Items | 46.80% | 25.43% | -12.28% | 9.96% | 24.70% |
| Change in Net Operating Assets | 131.57% | -3.31% | -162.83% | 614.92% | 15.43% |
| Cash from Operations | 113.93% | -25.46% | -267.14% | 269.71% | 47.07% |
| Capital Expenditure | -10.50% | -1,086.92% | 145.51% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -80.39% | 621.00% | 113.19% | -530.73% | -70.80% |
| Cash from Investing | -82.21% | 596.85% | 113.32% | -532.52% | -70.80% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 33.62% | -76.57% | -43.96% | 918.67% | -79.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 89.57% | -- | -- |
| Cash from Financing | 33.62% | -74.00% | -96.22% | 13,492.59% | -79.85% |
| Foreign Exchange rate Adjustments | -95.68% | 10,053.85% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.67% | 129.31% | -188.50% | 4,199.21% | -96.95% |